Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference76 articles.
1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89.
2. McCain J. Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: New and emerging treatment options. Vol. 39, P and T. Medi Media USA Inc; 2014. p. 130.
3. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. FDA [Internet] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer. Accessed 16 Oct 2021.
4. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103.
5. Zustovich F, Fabiani F. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Vol. 91, Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd; 2014; 197–209.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献